---
title: "LakeShore Biopharma (LSB.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LSB.US.md"
symbol: "LSB.US"
name: "LakeShore Biopharma"
industry: "Biotechnology"
---

# LakeShore Biopharma (LSB.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |

## Company Profile

LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-27T04:30:19.000Z

**Overall: C (0.59)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 183 / 402 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 7.41% |  |
| Net Profit YoY | 76.90% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 85.29M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -18.43% | E |
| Profit Margin | -16.26% | D |
| Gross Margin | 82.47% | A |

#### Growth Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 7.41% | C |
| Net Profit YoY | 76.90% | A |
| Total Assets YoY | -10.15% | E |
| Net Assets YoY | -15.11% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -615.07% | E |
| OCF YoY | 7.41% | C |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.43 | C |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 63.46% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - LakeShore Biopharma",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-18.43%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-16.26%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "82.47%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "C",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "7.41%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "76.90%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-10.15%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-15.11%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-615.07%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "7.41%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.43",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "63.46%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.86 | 281/602 | - | - | - |
| PB | 0.38 | 24/602 | 0.47 | 0.38 | 0.28 |
| PS (TTM) | 0.30 | 12/602 | 0.40 | 0.30 | 0.28 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/LSB.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LSB.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LSB.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.